Podcast
Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias

Released: February 26, 2021

Expiration: February 25, 2022

Jorge Cortes
Jorge Cortes, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1
Course Completed

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:  

  • The macrophage immune checkpoint inhibitor magrolimab in AML
  • The STAMP inhibitor asciminib in CML (the ASCEMBL trial)
  • Optimal dosing for the TKI ponatinib in CML

Presenters:

Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia

Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York